OncoTherapy Science, Inc. (FRA:30O)

Market Cap	43.34M +3.3%
Revenue (ttm)	4.26M +10.9%
Net Income	-4.79M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3
Open	0.0900
Previous Close	0.0900
Day's Range	0.0900 - 0.0900
52-Week Range	0.0830 - 0.1940
Beta	n/a
RSI	50.13
Earnings Date	Feb 6, 2026

About OncoTherapy Science

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stag...

• Industry: Commercial Physical and Biological Research
• Founded: 2001
• Employees: 47
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 30O

Financial Performance

In fiscal year 2025, OncoTherapy Science's revenue was 750.00 million, an increase of 22.95% compared to the previous year's 610.00 million. Losses were -815.00 million, -36.72% less than in 2024.

Financial numbers in JPY